Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary ...

24 August 2026 · By · Wire by Fusion42

Published

24 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

United States

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 24 August 2026 · Fusion42 review

Tempus received FDA 510(k) clearance for its AI software, Tempus ECG-PH, which analyzes standard 12-lead ECGs to detect signs of pulmonary hypertension, expanding its portfolio of FDA-cleared cardiovascular AI tools.

This Wire brief sits within Fusion42's coverage of Health, and 4 sources have reported it between 24 Aug 2026 and 28 Aug 2026.

◆ ◆ The Wire takeaway

Tempus' new FDA clearance opens a regulatory door for AI medical tools that detect difficult-to-diagnose heart conditions early. You in digital health can now push earlier screening tools into clinical workflows with less regulatory friction.

◆ Coverage

4 sources · first reported 24 Aug 2026 · latest 28 Aug 2026

◆ Related on Wire

◆ Topics

Healthfda-clearancecardiovascular-aipulmonary-hypertensionecg-analysishealthtech